Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEULARK: NEU-411 in Early Parkinson's Disease
NCT06680830Phase 2Recruiting
- Sponsor
- Neuron23
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing NEU-411 with Placebo (2 arms). Primary endpoints: Roche digital biomarker score at 52 weeks and Incidence of treatment-emergent adverse events and serious adverse events at 54 weeks. Started Jan 2025; status: recruiting.
02
Drugs
NEU-411
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06680830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680830.